Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma (MM) is a progressive plasma cell malignancy with increasing global incidence.
• Despite advancements, MM remains incurable, necessitating novel therapeutic strategies.
• Current treatments include stem cell transplantation for eligible patients.

Purpose of the Study:

• To review and compare CAR T cell therapy (CAR) and bispecific T cell engagers (BiTE) for multiple myeloma.
• To discuss the potential of T cell-based immunotherapies in MM treatment.
• To explore the role of these immunotherapies as bridging therapies to transplant.

Main Methods:

• Comprehensive review of existing clinical literature on CAR T cell therapy and BiTE in MM.
• Comparative analysis of CAR T cell therapy and BiTE efficacy and safety.
• Discussion of emerging therapeutic targets and future clinical trial designs.

Main Results:

• CAR T cell therapy and BiTE target various MM surface antigens including BCMA, SLAMF7, GPRC5D, FCRH5, and CD38.
• Evidence suggests early immunotherapy administration may enhance patient outcomes.
• These immunotherapies are being investigated for their potential to improve MM treatment paradigms.

Conclusions:

• CAR T cell therapy and BiTE represent promising T cell-based immunotherapies for multiple myeloma.
• Early integration of these therapies could significantly impact MM patient outcomes.
• Further research and clinical trials are warranted to optimize their use, potentially as bridging therapies.